Combination of Isosorbide Dinitrate and Hydralazine in Blacks with Heart Failure
The DOI matches its Crossref record, with a small difference in title or year; 61 of the 61 references it cites were found in a registry or an index.
Abstract
BACKGROUND: We examined whether a fixed dose of both isosorbide dinitrate and hydralazine provides additional benefit in blacks with advanced heart failure, a subgroup previously noted to have a favorable response to this therapy. METHODS: A total of 1050 black patients who had New York Heart Association class III or IV heart failure with dilated ventricles were randomly assigned to receive a fixed dose of isosorbide dinitrate plus hydralazine or placebo in addition to standard therapy for heart failure. The primary end point was a composite score made up of weighted values for death from any cause, a first hospitalization for heart failure, and change in the quality of life. RESULTS: The study was terminated early owing to a significantly higher mortality rate in the placebo group than in the group given isosorbide dinitrate plus hydralazine (10.2 percent vs. 6.2 percent, P=0.02). The mean primary composite score was significantly better in the group given isosorbide dinitrate plus hydralazine than in the placebo group (-0.1+/-1.9 vs. -0.5+/-2.0, P=0.01; range of possible values, -6 to +2), as were its individual components (43 percent reduction in the rate of death from any cause [hazard ratio, 0.57; P=0.01] 33 percent relative reduction in the rate of first hospitalization for heart failure [16.4 percent vs. 22.4 percent, P=0.001], and an improvement in the quality of life [change in score, -5.6+/-20.6 vs. -2.7+/-21.2, with lower scores indicating better quality of life; P=0.02; range of possible values, 0 to 105]). CONCLUSIONS: The addition of a fixed dose of isosorbide dinitrate plus hydralazine to standard therapy for heart failure including neurohormonal blockers is efficacious and increases survival among black patients with advanced heart failure.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The primary outcome was a weighted score, but individual components of the outcome showed a difference favouring H-ISDN for all-cause mortality, first HHF, and change in quality of life score.”
From CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction (2021) · cites this paper as [79]
In the citing paper
“Digoxin may reduce the risk of HF hospitalization in patients with HFrEF treated with ACE-Is, irrespective of diabetes status.519”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [519]
Citations
Cites
Pfeffer, M. A., Braunwald, E., Moyé, L. A., Basta, L., Brown, E. J., Cuddy, T. E., Davis, B. R., Geltman, E. M., Goldman, S., Flaker, G. C., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199209033271001 · Cited by 5,911
Effects of Enalapril on Mortality in Severe Congestive Heart Failure
The Consensus Trial Study Group* (1987) · New England Journal of Medicine · doi:10.1056/nejm198706043162301 · Cited by 5,121
Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress
Cai, H., & Harrison, D. G. (2000) · Circulation Research · doi:10.1161/01.res.87.10.840 · Cited by 3,839
A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure
Cohn, J. N., & Tognoni, G. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010713 · Cited by 3,108
Self-citationEffect of carvedilol on survival in severe chronic heart failure
Packer, M., Coats, A. J. S., Fowler, M. B., Katus, H. A., Krum, H., Mohacsi, P., Rouleau, J. L., Tendera, M., Castaigne, A., Roecker, E. B., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105313442201 · Cited by 3,093
Cohn, J. N., Johnson, G., Ziesche, S., Cobb, F., Francis, G., Tristani, F., Smith, R., Dunkman, W. B., Loeb, H., Wong, M., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199108013250502 · Cited by 2,833
Self-citationSuperoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor
Gryglewski, R. J., Palmer, R. M. J., & Moncada, S. (1986) · Nature · doi:10.1038/320454a0 · Cited by 2,400
Effect of Vasodilator Therapy on Mortality in Chronic Congestive Heart Failure
Cohn, J. N., Archibald, D. G., Ziesche, S., Franciosa, J. A., Harston, W. E., Tristani, F. E., Dunkman, W. B., Jacobs, W., Francis, G. S., Flohr, K. H., et al. (1986) · New England Journal of Medicine · doi:10.1056/nejm198606123142404 · Cited by 2,400
Self-citationEffect of carvedilol on survival in severe chronic heart failure
Packer, M., Coats, A. J. S., & Fowler, M. B. (2001) · ACC Current Journal Review · doi:10.1016/s1062-1458(01)00477-9 · Cited by 1,661
Cited by
Items 501–600 of 1,001
Cohn, J. N., Cleland, J. G. F., Lubsen, J. C., BORER, J. S., Steg, P. G., Perelman, M., & Zannad, F. M. (2008) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2008.10.029 · Cited by 37
Self-citationDilated Cardiomyopathy: From Genetics to Clinical Management
(2019) · doi:10.1007/978-3-030-13864-6 · Cited by 32
Ventetuolo, C. E., Lima, J. A. C., Barr, R. G., Bristow, M. R., Bagiella, E., Chahal, H., Kizer, J. R., Lederer, D. J., Bluemke, D. A., & Kawut, S. M. (2012) · Pulmonary Circulation · doi:10.4103/2045-8932.101657 · Cited by 32
“African Americans may have greater nitric oxide de icits and endothelial damage than Caucasians (and therefore may be less likely to respond to RAS manipulation).[40,41] In the RV, we have shown that African Americans have lower RV mass and less RV hypertrophy when compared to Caucasians after adjustment for LV mass,…”
BackgroundInpatient management of acute decompensated heart failure
Raj, L. M., Maidman, S. D., & Adhyaru, B. B. (2019) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2019-136742 · Cited by 36
Farag, M., Mabote, T., Shoaib, A., Zhang, J., Nabhan, A. F., Clark, A. L., & Cleland, J. G. F. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.05.160 · Cited by 32
Heart Failure in Diabetes and Related Conditions
Kamalesh, M. (2007) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2007.07.007 · Cited by 37
Evaluation of adverse drug reactions reported to a poison control center between 2000 and 2007
Vassilev, Z. P., Chu, A. F., Ruck, B. E., Adams, E. H., & Marcus, S. M. (2009) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp080267 · Cited by 32
A Patient with Heart Failure and Worsening Kidney Function
Sarnak, M. J. (2014) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.11601113 · Cited by 37
Race-based therapy for hypertension: possible benefits and potential pitfalls
Ferdinand, K. C., & Ferdinand, D. P. (2008) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.6.10.1357 · Cited by 32
“Circulation 110(22), 3488–3492 (2004). Wattigney WA, Webber LS, Srinivasan SR, 9”
Self-citationMünzel, T. F., Genth‐Zotz, S., & Hink, U. (2007) · Hypertension · doi:10.1161/hypertensionaha.106.085456 · Cited by 33
Ghio, S., Bonderman, D., Felix, S. B., Ghofrani, H. A., Michelakis, E. D., Mitrović, V. L., Oudiz, R. J., Frey, R., Roessig, L., & Semigran, M. J. (2012) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfs071 · Cited by 33
Are Genetic Tests for Atherosclerosis Ready for Routine Clinical Use?
Paynter, N. P., Ridker, P. M., & Chasman, D. I. (2016) · Circulation Research · doi:10.1161/circresaha.115.306360 · Cited by 36
Organic Nitrates and Nitrate Tolerance—State of the Art and Future Developments
Daiber, A., Münzel, T. F., & Gori, T. (2010) · Advances in pharmacology · doi:10.1016/b978-0-12-385061-4.00007-6 · Cited by 34
Keulenaer, G. W. D., Segers, V. F. M., Zannad, F. M., & Brutsaert, D. L. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.735 · Cited by 34
Ameri, P., Bertero, E., Maack, C., Teerlink, J. R., Rosano, G. M. C., & Metra, M. (2021) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvab033 · Cited by 33
Management of Heart Failure With Reduced Ejection Fraction
Rashid, A. M., Khan, M. S., Fudim, M., DeWald, T. A., DeVore, A. D., & Butler, J. (2023) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2023.101596 · Cited by 35
Mau, M. K. L. M., West, M. R., Shara, N. M., Efird, J. T., Alimineti, K., Saito, E., Sugihara, J. G., & Ng, R. C. K. (2007) · Ethnicity and Health · doi:10.1080/13557850601081720 · Cited by 31
Role of xanthine oxidoreductase in cardiac nitroso-redox imbalance
Τζιόμαλος, Κ., & Hare, J. M. (2009) · Frontiers in bioscience · doi:10.2741/3243 · Cited by 31
“249 The pivotal role of nitroso-redox balance in cardiovascular homeostasis and more specifically in HF is also supported by clinical studies showing that combined administration of nitrates and hydralazine reduced mortality in HF regardless of its severity (166, 167).”
BackgroundMason, R. P., Kubant, R., Jacob, R. F., Malinski, P. T., Huang, X., Louka, F. R., Borowiec, J. W., Mizuno, Y., & Maliñski, T. (2009) · American Journal of Hypertension · doi:10.1038/ajh.2009.163 · Cited by 31
Drug Therapy of Dyslipidemia in the Elderly
Yandrapalli, S., Gupta, S., Andries, G., Cooper, H. A., & Aronow, W. S. (2019) · Drugs & Aging · doi:10.1007/s40266-018-00632-x · Cited by 32
Inhibitors of cyclic nucleotide phosphodiesterase 3 and 5 as therapeutic agents in heart failure
Stehlik, J., & Movsesian, M. A. (2006) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.15.7.733 · Cited by 31
“This systemic vasodilatory effect may be important as other systemic vasodilators (angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, hydralazine and nitrates) have been shown to reduce morbidity and mortality in chronic heart failure [65-70].”
BackgroundHaga, S. B., & Ginsburg, G. S. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.04.017 · Cited by 30
Rosendorff, C., Rosendorff, C., Lackland, D. T., Allison, M., Aronow, W. S., Black, H. R., Blumenthal, R. S., Cannon, C. P., de Lemos, J. A., Elliott, W. J., et al. (2015) · The American Journal of Medicine · doi:10.1016/j.amjmed.2015.10.045 · Cited by 32
Genomics and Cardiovascular Disease
Frazier, L. Q., Johnson, R. L., & Sparks, E. A. (2005) · Journal of Nursing Scholarship · doi:10.1111/j.1547-5069.2005.00055.x · Cited by 30
Vascular health and cognitive function in older adults with cardiovascular disease
Forman, D. E., Cohen, R. A., Hoth, K. F., Haley, A. P., Poppas, A., Moser, D. J., Gunstad, J., Paul, R. H., Jefferson, A. L., Tate, D. F., et al. (2008) · Artery Research · doi:10.1016/j.artres.2008.01.001 · Cited by 34
Elkayam, U., & Bitar, F. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.07.031 · Cited by 30
Cheng, J. W. M. (2006) · Clinical Therapeutics · doi:10.1016/j.clinthera.2006.05.007 · Cited by 35
Cheng, H., Yu, W., Sung, S., Wang, K., Chuang, S., & Chen, C. (2008) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2008.09.003 · Cited by 30
“In 1050 black patients who had New York Heart Association class III or IV heart failure with dilated ventricles, a fixed dose of isosorbide dinitrate plus hydralazine in addition to standard therapy for heart failure significantly improved the rate of death from any cause, the rate of first hospitalisation for heart f…”
BackgroundRace, Pharmacogenomics, and Marketing: Putting BiDil in Context
Kahn, J. (2006) · The American Journal of Bioethics · doi:10.1080/15265160600755789 · Cited by 30
“However, the trial on which the BiDil submission was based, the African American Heart Failure Trial (A-HeFT), enrolled only self-identified African Americans ( Taylor et al. 2004 ).”
BackgroundWhittle, J., Kressin, N. R., Peterson, E. D., Orner, M. B., Glickman, M. E., Mazzella, M., & Petersen, L. A. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.12.059 · Cited by 32
Sharma, K., Hill, T., Grams, M. E., Daya, N. R., Hays, A. G., Fine, D. M., Thiemann, D. R., Weiss, R. G., Tedford, R. J., Kass, D. A., et al. (2015) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2015.08.019 · Cited by 29
Zaya, M., Phan, A., & Schwarz, E. R. (2011) · Heart Failure Reviews · doi:10.1007/s10741-011-9256-0 · Cited by 31
Gasparyan, S. B., Buenconsejo, J., Kowalewski, E. K., Oscarsson, J., Bengtsson, O., ESTERLINE, R. L., Koch, G. G., Berwanger, O. B., & Kosiborod, M. (2022) · Therapeutic Innovation & Regulatory Science · doi:10.1007/s43441-022-00420-1 · Cited by 34
“using mean and standard deviation, see for example [14]).”
MethodHeart Failure in Very Old Adults
Forman, D. E., Ahmed, A., & Fleg, J. L. (2013) · Current Heart Failure Reports · doi:10.1007/s11897-013-0163-7 · Cited by 31
Aspectos clínicos e terapêuticos da insuficiência cardíaca por doença de Chagas
Braga, J. C. V., dos Reis, F. J. F. B., Aras, R., Costa, N. D., Bastos, C. J. D. C., Silva, R. V. D. S., Soares, A. C. M., Júnior, A. M., Ásfora, S., & Latado, A. L. (2006) · Arquivos Brasileiros de Cardiologia · doi:10.1590/s0066-782x2006000400010 · Cited by 29
Yandrapalli, S., Aronow, W. S., Mondal, P., & Chabbott, D. R. (2017) · Archives of Medical Science · doi:10.5114/aoms.2017.68813 · Cited by 32
“Since then, ACEIs [10, 11], β-blockers [12–14], aldosterone antagonists [15–17], ARBs [18, 19], and the combination of isosorbide dinitrate and hydralazine [20] have been approved for the treatment of HFrEF.”
BackgroundButler, J., Packer, M., Greene, S. J., Fiuzat, M., Anker, S. D., Anstrom, K. J., Carson, P. E., Cooper, L. B., Fonarow, G. C., Hernandez, A. F., et al. (2019) · Circulation · doi:10.1161/circulationaha.119.042155 · Cited by 30
Self-citationPharmacological treatment of chronic heart failure
Adorisio, R., Luca, L. D., Rossi, J. S., & Gheorghiade, M. (2006) · Heart Failure Reviews · doi:10.1007/s10741-006-9482-z · Cited by 30
“In fact, worsening symptoms and increased mortality have been reported, possibly because of their negative inotropic effect and reflex neurohormonal activation [ 95 , 97].”
BackgroundChen, F. C., Ogut, O., Rhee, A. Y., Hoit, B. D., & Brozovich, F. V. (2006) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2006.05.018 · Cited by 29
Walsh, M. N., Yancy, C. W., Albert, N. M., Curtis, A. B., Gheorghiade, M., Heywood, J. T., Inge, P. J., McBride, M. L., Mehra, M. R., O'Connor, C. M., et al. (2010) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2010.07.250 · Cited by 30
Self-citationPharmacogenetics, Race, and Psychiatry: Prospects and Challenges
Jones, D. S., & Perlis, R. H. (2006) · Harvard Review of Psychiatry · doi:10.1080/10673220600642895 · Cited by 32
Nebivolol in the treatment of chronic heart failure.
Veverka, A., & Salinas, J. L. (2007) · PubMed Central · Cited by 29
Intensive Session: New Approaches to Medical Issues in Long-Term Care
Messinger‐Rapport, B. J., Morley, J. E., Thomas, D. R., & Gammack, J. K. (2007) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2007.07.002 · Cited by 29
Outram, S. M., & Ellison, G. T. H. (2005) · Journal of Biosocial Science · doi:10.1017/s0021932005000921 · Cited by 30
“Bubb & Matthews, 2004) and treatment (such as the development of separate guidelines and therapies for different racial/ethnic groups; e.g. Williams et al., 2004; Taylor et al., 2004), and indirectly, in terms of the readiness to view racial/ethnic health disparities as innate and beyond the scope of public health int…”
BackgroundNHG-Standaard Hartfalen: Tweede herziening
Hoes, A. W., Voors, A., Rutten, F. H., van Lieshout, J., Janssen, P. G. H., & Walma, E. (2011) · Bohn Stafleu van Loghum eBooks · doi:10.1007/978-90-313-8279-8_24 · Cited by 29
Heart Failure Management: The Present and the Future
Jameel, M. N., & Zhang, J. J. (2009) · Antioxidants and Redox Signaling · doi:10.1089/ars.2009.2488 · Cited by 33
“A combination of isosorbide dinitrate and hydralazine, in addition to standard therapy, has been shown to improve survival in black patients with heart failure (161).”
Pharmacogenetic Studies of Antidepressant Response: How Far from the Clinic?
Perlis, R. H. (2007) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2006.12.004 · Cited by 30
Freedman, B. I., Bowden, D. W., Sale, M. M., Langefeld, C. D., & Rich, S. S. (2006) · Hypertension · doi:10.1161/01.hyp.0000227047.26988.3e · Cited by 28
Ziaeian, B., Fonarow, G. C., & Heidenreich, P. A. (2017) · JACC Heart Failure · doi:10.1016/j.jchf.2017.04.008 · Cited by 29
“The period of observation mirrors that from the A-HeFT (7).”
MethodResultInfluentialZueger, P., Kumar, V. M., Harrington, R. L., Rigoni, G., Atwood, A., DiDomenico, R. J., & Touchette, D. R. (2018) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2108 · Cited by 28
Disparities in cardiovascular care: Past, present, and solutions
Youmans, Q. R., Hasting-Spaine, L., Princewill, O., Shobayo, T. O., & Okwuosa, I. S. (2019) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.86a.18088 · Cited by 31
Thadani, U., & Ripley, T. L. (2007) · Expert Opinion on Drug Safety · doi:10.1517/14740338.6.4.385 · Cited by 29
“Recently, African–American Heart Failure (A-HeFT) investigators demonstrated the benefit of using ISDN and hydralazine in black patients with chronic heart failure due to systolic dysfunction [54] .”
BackgroundThe Food and Drug Administration and pragmatic clinical trials of marketed medical products
Anderson, M. L., Griffin, J. C. M., Goldkind, S. F., Zeitler, E. P., Wing, L., Al‐Khatib, S. M., & Sherman, R. E. (2015) · Clinical Trials · doi:10.1177/1740774515597700 · Cited by 31
Boerrigter, G., & Burnett, J. C. J. (2009) · Circulation · doi:10.1161/circulationaha.109.860288 · Cited by 28
Endothelial dysfunction in African-Americans
Patel, P. D., Velazquez, J. L., & Arora, R. R. (2008) · International Journal of Cardiology · doi:10.1016/j.ijcard.2008.10.007 · Cited by 27
Update on Peripartum Cardiomyopathy
Cruz, M., Briller, J. E., & Hibbard, J. U. (2010) · Obstetrics and Gynecology Clinics of North America · doi:10.1016/j.ogc.2010.02.003 · Cited by 27
“The combination of hydralazine and nitrates is considered to be a reasonable addition to standard therapy in symptomatic patients and some racial groups.(78,85) Amlodipine is an additional option for vasodilator”
BackgroundCardiac Radionuclide Imaging to Assess Patients With Heart Failure
Travin, M. I. (2014) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2014.04.005 · Cited by 27
Ganiats, T. G., Konstam, M. A., MANCINI, D. M., Abraham, W. T., Casey, D. E., Feldman, A. M., & Ma, G. S. (2009) · Cited by 27
Packer, M. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.623 · Cited by 28
Diseases of the Cardiovascular System
Lockhart, P. B., & Sun, Y. (2021) · Wiley eBooks · doi:10.1002/9781119597797.ch14 · Cited by 32
Allelic variants of SCN5A and risk of sudden cardiac arrest in patients with coronary artery disease
Stecker, E. C., Sono, M., Wallace, E. R., Gunson, K., Jui, J., & Chugh, S. S. (2006) · Heart Rhythm · doi:10.1016/j.hrthm.2006.01.029 · Cited by 27
Mismatch between heart failure patients in clinical trials and the real world
Niederseer, D., Thaler, C. W., Niederseer, M. C., & Niebauer, J. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2012.12.069 · Cited by 28
“Therefore the A-HeFT study [22] was performed, showing that isosorbide dinitrate and hydralazine are also effective in African Americans.”
MethodHeart Failure and Sudden Cardiac Death
Saour, B., Smith, B., & Yancy, C. W. (2017) · Cardiac Electrophysiology Clinics · doi:10.1016/j.ccep.2017.07.010 · Cited by 30
Self-citationRace and Ethnicity in the Era of Emerging Pharmacogenomics
Harty, L. C., Johnson, K. J., & Power, A. (2006) · The Journal of Clinical Pharmacology · doi:10.1177/0091270005286028 · Cited by 27
If direct-to-consumer advertisements come to Europe: lessons from the USA
Metzl, J. M. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60321-3 · Cited by 27
Recent changes in the landscape of combination RAS blockade
Epstein, B. J., Smith, S. M., & Choksi, R. R. (2009) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.09.127 · Cited by 27
Ferdinand, K. C. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.12.013 · Cited by 27
Self-citationHeart failure, post-hospital mortality and renal function in Tanzania: A prospective cohort study
Kingery, J. R., Yango, M., Wajanga, B. M. K., Kalokola, F., Brejt, J. A., Kataraihya, J. B., & Peck, R. N. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.05.025 · Cited by 29
Petersen, K. E., Prows, C. A., Martin, L. J., & Maglo, K. N. (2014) · Public Health Genomics · doi:10.1159/000362359 · Cited by 26
Chioncel, O. D., Mebazaa, A., Farmakis, D. T., Abdelhamid, M., Lund, L. H., Harjola, V., Anker, S. D., Filippatos, G., Gal, T. B., Damman, K., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.3673 · Cited by 26
Ghali, J. K., Tam, S. W., Sabolinski, M. L., Taylor, A. L., Lindenfeld, J. M., Cohn, J. N., & Worcel, M. (2008) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2008.07.189 · Cited by 26
Self-citationEvidence-Based Therapy for Heart Failure
DEEDWANIA, P. C., & Carbajal, E. V. (2012) · Medical Clinics of North America · doi:10.1016/j.mcna.2012.07.010 · Cited by 26
Heart failure in the elderly: advances and challenges
Jugdutt, B. I. (2010) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.10.36 · Cited by 27
Margolin, E., Huynh, T., Brann, A. M., & Greenberg, B. (2024) · JACC Advances · doi:10.1016/j.jacadv.2023.100818 · Cited by 26
Hypertension in ethnic groups: epidemiological and clinical perspectives
Dwivedi, G., & Beevers, D. G. (2009) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.09.88 · Cited by 26
Acute Heart Failure in the African American Patient
Cuyjet, A. B., & Akinboboye, O. (2014) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2014.04.018 · Cited by 28
When to Stop a Clinical Trial Early for Benefit: Lessons Learned and Future Approaches
Zannad, F. M., Stough, W. G., McMurray, J. J. V., Remme, W. J., Pitt, B., BORER, J. S., Geller, N. L., & Pocock, S. (2012) · Circulation Heart Failure · doi:10.1161/circheartfailure.111.965707 · Cited by 28
Contemporary Management of Heart Failure in the Elderly
Osmanska, J., & Jhund, P. S. (2018) · Drugs & Aging · doi:10.1007/s40266-018-0625-4 · Cited by 28
“However, the subgroup of patients of African descent did appear to gain benefit and in the subsequent African-American Heart Failure Trial (A-HeFT) [28], the combination reduced the primary endpoint of all-cause death or HF hospitalisation.”
BackgroundHydralazine-associated adverse events: a report of two cases of hydralazine-induced ANCA vasculitis
Zuckerman, R., Patel, M., Costanzo, E. J., Dounis, H., Haj, R. A., Seyedali, S., & Asif, A. (2018) · Brazilian Journal of Nephrology · doi:10.1590/2175-8239-jbn-3858 · Cited by 26
Saudi Heart Association (SHA) guidelines for the management of heart failure
AlHabeeb, W., Alayoubi, F., Alghalayini, K. W., Ghofaili, F. A., Hebaishi, Y. A., Al‐Jazairi, A. S., Al-Mallah, M. H., Almasood, A. S., Qaseer, M. A., AlSaif, S. M., et al. (2019) · Journal of the Saudi Heart Association · doi:10.1016/j.jsha.2019.06.004 · Cited by 30
“In addition, an RCT conducted in self-identified patients of African descent found that the addition of hydralazine and isosorbide dinitrate reduced mortality and HF hospitalization in patients with HFrEF (NYHA Class III–IV), compared with conventional therapy (ACE-Is, beta-blockers, and MRAs) [76].”
BackgroundOutcomes by Race and Etiology of Patients With Left Ventricular Systolic Dysfunction
Thomas, K. L., East, M. A., Velazquez, E. J., Tuttle, R. H., Shaw, L. K., O’Connor, C. M., & Peterson, E. D. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.07.002 · Cited by 26
The Economics of Heart Failure
Kazi, D. S., & Mark, D. B. (2012) · Heart Failure Clinics · doi:10.1016/j.hfc.2012.09.005 · Cited by 28
Pharmacogenetics and ethnically targeted therapies
Rahemtulla, T., & Bhopal, R. S. (2005) · BMJ · doi:10.1136/bmj.330.7499.1036 · Cited by 26
Effects of Advancing Gestation and Non-Caucasian Race on Ductus Arteriosus Gene Expression
Waleh, N. S., Barrette, A. M., Dagle, J. M., Momany, A. M., Jin, C., Hills, N. K., Shelton, E. L., Reese, J., & Clyman, R. I. (2015) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2015.07.011 · Cited by 25
Steinberg, R., Udeshi, E., Dickert, N. W., Quyyumi, A. A., Chirinos, J. A., & Morris, A. A. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.122.027666 · Cited by 25
“31 Whereas organic nitrates have been thought to reduce wave reflection, this may not be true in all populations, at least with chronic therapy.”
BackgroundMacDonald, B. J., Virani, S., Zieroth, S. R., & Turgeon, R. D. (2023) · CJC Open · doi:10.1016/j.cjco.2023.05.008 · Cited by 30
“The ESC further specifies use in Black patients with NYHA class 3-4 symptoms and either LVEF < 45% with a dilated left ventricle, or LVEF 35%, strictly reflecting the African-American Heart Failure Trial (A-HeFT) trial inclusion criteria, from which these recommendations are derived.(29) Finally, both the CCS and the…”
BackgroundPharmacologic Therapy of Chronic Heart Failure
Hamad, E., Mather, P. J., Srinivasan, S., Rubin, S., Whellan, D. J., & Feldman, A. M. (2007) · American Journal of Cardiovascular Drugs · doi:10.2165/00129784-200707040-00002 · Cited by 27
Zhou, R., & Frishman, W. H. (2010) · Cardiology in Review · doi:10.1097/crd.0b013e3181d74582 · Cited by 29
Radiosensitization of HT‐29 cells and xenografts by the nitric oxide donor DETANONOate
Gao, X., Saha, D., Kapur, P., Anthony, T., Livingston, E. H., & Huerta, S. (2009) · Journal of Surgical Oncology · doi:10.1002/jso.21318 · Cited by 25
Giblin, E. M., Adams, K. F., Hill, L., Fonarow, G. C., Williams, F. B., Sharma, P. P., Albert, N. M., Butler, J., DeVore, A. D., Duffy, C. I., et al. (2019) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2019.09.020 · Cited by 25
Self-citationBlood, A. J., Fischer, C. M., Fera, L. E., MacLean, T. E., Smith, K. V., Dunning, J. R., Bosque-Hamilton, J. W., Aronson, S., Gaziano, T. A., MacRae, C. A., et al. (2019) · Clinical Cardiology · doi:10.1002/clc.23291 · Cited by 25
Use of nitrates in ischemic heart disease
Cocco, G., Jerie, P., & Iselin, H.-U. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1052742 · Cited by 28
Chiang, C., Hung, C., Wu, Y., Lin, T., Ueng, K., Sung, S., Wu, C., Chao, T., Lin, H., Lin, Y., et al. (2023) · PubMed Central · doi:10.6515/acs.202305_39(3).20230301a · Cited by 30
Damman, K., ter Maaten, J. M., Mayne, K. J., Bolignano, D., Brown, E. M., da Costa, B. R., Dagre, A. G., Gansevoort, R. T., Gavina, C., Goette, A., et al. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag098 · Cited by 33
Contemporary Medical Management of Systolic Heart Failure
Nair, A. P., Timoh, T., & Fuster, V. (2012) · Circulation Journal · doi:10.1253/circj.cj-11-1424 · Cited by 25
Packer, M. (2016) · Circulation Heart Failure · doi:10.1161/circheartfailure.116.002837 · Cited by 26
Hashemi, D., Motzkus, L. A., Blum, M., Kraft, R., Tanacli, R., Tahirović, E., Doeblin, P., Zieschang, V., Zamani, S. M., Kelm, M., et al. (2021) · ESC Heart Failure · doi:10.1002/ehf2.13193 · Cited by 24
Loss of cardiomyocyte CYB5R3 impairs redox equilibrium and causes sudden cardiac death
Carew, N. T., Schmidt, H. M., Yuan, S. S., Galley, J. C., Hall, R. M., Altmann, H. M., Hahn, S. A., Miller, M. P., Wood, K. C., Gabris, B. E., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci147120 · Cited by 26
“The GRAHF cohort was a genetic substudy of the AHeFT trial (ClinicalTrials.gov NCT00047775) (41, 42).”
InfluentialSeidu, S., Lawson, C. A., Kunutsor, S. K., Khunti, K., & Rosano, G. M. C. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3108 · Cited by 26
Pharmacogenomics and the Challenge of Health Disparities
Lee, S. S. (2009) · Public Health Genomics · doi:10.1159/000189630 · Cited by 24
“Nitromed focuses on putative biological differences among groups by focusing on a hypothesis of impaired bioavailability of nitric oxide, which is thought to contribute to the structural remodeling of the left ventricle that increases the rate of death and complications. The company suggests that African-American pati…”
Background
Metadata
- Authors
- Taylor, A. L., Ziesche, S., Yancy, C., Carson, P., D'Agostino, R., Ferdinand, K., Taylor, M., Adams, K., Sabolinski, M., Worcel, M., & Cohn, J. N.
- Affiliations
- University of Minnesota (US)
- United States Department of Veterans Affairs (US)
- The University of Texas Southwestern Medical Center (US)
- Veterans Health Administration (US)
- Xavier University of Louisiana (US)
- Association of Black Cardiologists (US)
- University of North Carolina at Chapel Hill (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-11-11
- Volume
- 351
- Issue
- 20
- Pages
- 2049-2057
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2140023412
- Cited by
- 1,773
- References
- 61
- Citations by year
- 2026: 28 · 2025: 30 · 2024: 43 · 2023: 67 · 2022: 68 · 2021: 70 · 2020: 76 · 2019: 53 · 2018: 58 · 2017: 90 · 2016: 78 · 2015: 79 · 2014: 76 · 2013: 78 · 2012: 97
- FWCI
- 84.29
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Keywords
- isosorbide dinitrate, hydralazine, advanced heart failure, Black patients, fixed-dose combination, mortality, heart failure hospitalization, quality of life, dilated ventricles
- MeSH terms
- Adult, Aged, Double-Blind Method, Drug Combinations, Drug Therapy, Combination, Female, Heart Failure, Humans, Hydralazine, Isosorbide Dinitrate, Male, Middle Aged, Quality of Life, Vasodilator Agents, Survival Analysis, Treatment Outcome, Nitric Oxide Donors, Black People
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.